Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Prepaid Assets (2020 - 2025)

SAB Biotherapeutics' Prepaid Assets history spans 6 years, with the latest figure at $3.5 million for Q4 2025.

  • For Q4 2025, Prepaid Assets rose 18.03% year-over-year to $3.5 million; the TTM value through Dec 2025 reached $3.5 million, up 18.03%, while the annual FY2025 figure was $3.5 million, 18.03% up from the prior year.
  • Prepaid Assets reached $3.5 million in Q4 2025 per SABSW's latest filing, up from $1.8 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $3.6 million in Q2 2025 to a low of $102742.0 in Q3 2021.
  • Average Prepaid Assets over 5 years is $1.9 million, with a median of $1.9 million recorded in 2024.
  • Peak YoY movement for Prepaid Assets: surged 1038.56% in 2022, then plummeted 59.57% in 2023.
  • A 5-year view of Prepaid Assets shows it stood at $2.6 million in 2021, then tumbled by 43.33% to $1.5 million in 2022, then skyrocketed by 56.68% to $2.3 million in 2023, then grew by 27.16% to $3.0 million in 2024, then grew by 18.03% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Prepaid Assets are $3.5 million (Q4 2025), $1.8 million (Q3 2025), and $3.6 million (Q2 2025).